Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering
Question
Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering
Direct answer
Equity issuance at $64.00 per share sets an immediate liquidity benchmark and dilutes existing equity while convertible hedging may pressure spot shares. — bearish pressure on PCVX via equity dilution and convertible note arbitrage delta selling.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-07
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering”, revision 1, evidence through 2026-10-07. https://marketontology.com/catalysts/2026-10-07/vaxcyte-prices-1-0b-concurrent-common-stock-and-convertible-notes-offering-cdd9ae
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| PCVX | ▼Bear | 1–5 days | equity dilution and convertible note arbitrage delta selling | 56 |
Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering
Equity issuance at $64.00 per share sets an immediate liquidity benchmark and dilutes existing equity while convertible hedging may pressure spot shares. — bearish pressure on PCVX via equity dilution and convertible note arbitrage delta selling.
Vaxcyte announced pricing of 7.4 million shares at $64.00 and $500 million of 1.50% convertible senior notes.
- SourceVaxcyte announced pricing of 7.4 million shares at $64.00 and $500 million of 1.50% convertible senior notes.
- TransmissionEquity issuance at $64.00 per share sets an immediate liquidity benchmark and dilutes existing equity while convertible hedging may pressure spot shares.
- SummaryVaxcyte priced a $1.0 billion financing across equity and convertible debt. The 7.4 million share common offering was fixed at $64.00 per share. The company also placed $500 million of 1.50% convertible senior notes maturing in 2032.
- PCVXDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- PCVX closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- PCVX price vs. pre-event level
- PCVX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| PCVX | Bearishagreed | 66.96 2026-10-07 | -2.90% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes · news · 2026-10-07
Related catalysts
- 2026-10-07Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible OfferingPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 NotesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% ConvertiblesPCVX-2.90%
- 2026-10-07Vaxcyte prices $1 billion concurrent common stock and convertible note offeringsPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible NotesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt OfferingsPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible NotesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1 Billion Concurrent Public Offering of Stock and Convertible NotesPCVX-2.90%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.